GH Research PLC (GHRS)

GH Research PLC (GHRS) is a healthcare company (biotechnology) based in Ireland. The share price is $17.98, down 4.11% on the day, which values the company at $1.23B. Price as of 17 Nov 2026, 19:02 UTC, from Yahoo Finance.

Key facts

Share price
$17.98−4.11% today
Market value
$1.23B
200-week average
$12.9639% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

GH Research PLC in more detail

GHRS trades at -11.0× next year's expected earnings. It sits 39% above its 200-week average of $12.96.

In its favour: More cash than debt. Worth checking: Thin interest cover.

1 of the superinvestors tracked here hold GHRS, including Peter Kolchinsky (1.8% of the portfolio).

Superinvestors holding GHRS

1 of the investors tracked here report a position in their latest 13F filing.

GH Research PLC (GHRS): questions and answers

What is GH Research PLC's market cap?

GH Research PLC is valued at $1.23B at a share price of $17.98.

Is GHRS above its 200-week moving average?

Yes. GHRS is 38.7% above its 200-week average of $12.96. Long-term investors watch that line because strong companies rarely trade below it for long.

Does GHRS pay a dividend?

GH Research PLC does not currently pay a regular dividend.

Which famous investors own GHRS?

In their latest quarterly filings, Peter Kolchinsky (1.8% of the portfolio) hold GHRS. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “GH Research PLC (GHRS) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/GHRS

Underlying data: Yahoo Finance; company filings with the SEC.